Clinical Trials
16 trialsNCT05768139 2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT04072952 2026-04-15
mBC
Arvinas Inc.
Phase 1/2 Completed
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07002177 2026-01-07
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Forward Pharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03284957 2025-11-24
AMEERA-1
Sanofi
Phase 1/2 Terminated
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03304080 2025-07-18
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
Icahn School of Medicine at Mount Sinai
Phase 1/2 Active not recruiting
NCT02605486 2025-07-03
Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT06757335 2025-01-03
A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
Hinova Pharmaceuticals Inc.
Phase 1/2 Not yet recruiting
NCT04946864 2024-08-19
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Ascentage Pharma Group Inc.
Phase 1/2 Suspended
NCT03560531 2024-08-09
A Study of ZN-c5 in Subjects With Breast Cancer
Zeno Alpha Inc.
Phase 1/2 Completed
NCT03054363 2023-11-13
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
University of Colorado, Denver
Phase 1/2 Completed
NCT02448771 2022-10-24
A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT04669587 2022-03-22
ENZENO
EnhancedBio Inc.
Phase 1/2 Unknown
NCT01823835 2021-06-18
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Genentech, Inc.
Phase 1/2 Terminated